147450-30-4
Chemical Structure
Peripheral Myelin P0 Protein (180-199), mouse
- CAS No.: 147450-30-4
- Formula:C96H161N33O30S
- Molecular Weight:2289.57
IUPAC Name: (S)-3-((S)-2-((S)-2-((S)-2-((S)-2-((S)-2-((S)-2-((S)-1-(L-seryl-L-seryl-L-lysyl-L-arginylglycyl-L-arginyl-L-glutaminyl-L-threonyl)pyrrolidine-2-carboxamido)-3-methylbutanamido)-4-methylpentanamido)-3-(4-hydroxyphenyl)propanamido)propanamido)-4-(methylthio)butanamido)-4-methylpentanamido)-4-(((S)-1-(((S)-1-(((S)-1-(((S)-1-carboxy-2-hydroxyethyl)amino)-5-guanidino-1-oxopentan-2-yl)amino)-3-hydroxy-1-oxopropan-2-yl)amino)-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl)amino)-4-oxobutanoic acid
InChIKey: KYULDALAVVURPX-UYMUFCFZSA-N
SMILES: OC[C@H](N)C(N[C@@H](CO)C(N[C@@H](CCCCN)C(N[C@@H](CCCNC(N)=N)C(NCC(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCC(N)=O)C(N[C@@H]([C@H](O)C)C(N1[C@@H](CCC1)C(N[C@@H](C(C)C)C(N[C@@H](CC(C)C)C(N[C@H](C(N[C@@H](C)C(N[C@@H](CCSC)C(N[C@@H](CC(C)C)C(N[C@@H](CC(O)=O)C(N[C@H](C(N[C@@H](CO)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CO)C(O)=O)=O)=O)=O)CC2=CN=CN2)=O)=O)=O)=O)=O)CC3=CC=C(C=C3)O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O
Biological Activity: Peripheral Myelin P0 Protein (180-199), mouse is a neuritogenic peptide. Peripheral Myelin P0 Protein (180-199), mouse induces experimental autoimmune neuritis and enhances antibody production. Peripheral Myelin P0 Protein (180-199), mouse can be used in research on Guillain-Barré syndrome and experimental autoimmune neuritis[1][2][3][4][5][6][7][8][9][10][11][12].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Peripheral Myelin P0 Protein (180-199), mouse | 99.62% | Peripheral Myelin P0 Protein (180-199), mouse is a neuritogenic peptide. Peripheral Myelin P0 Protein (180-199), mouse induces experimental autoimmune neuritis and enhances antibody production. Peripheral Myelin P0 Protein (180-199), mouse can be used in research on Guillain-Barré syndrome and experimental autoimmune neuritis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Pineda AA, et al. Preventive and therapeutic effects of the selective Rho-kinase inhibitor fasudil on experimental autoimmune neuritis. Journal of the neurological sciences. 2011 Jul 15;306(1-2):115-20.
- [2]. Yu S, et al. Increased susceptibility to experimental autoimmune neuritis after upregulation of the autoreactive T cell response to peripheral myelin antigen in apolipoprotein E-deficient mice. Journal of neuropathology and experimental neurology. 2004 Feb;63(2):120-8.
- [3]. Beaino W, et al. Thiopalmitoylated peptides from the peripheral nervous system myelin p0 protein: synthesis, characterization, and neuritogenic properties. Bioconjugate chemistry. 2010 Aug 18;21(8):1439-47.
- [4]. Zhang HL, et al. Attenuated EAN in TNF-α deficient mice is associated with an altered balance of M1/M2 macrophages. PloS one. 2012;7(5):e38157.
- [5]. Kim HJ, et al. Targeting of myelin protein zero in a spontaneous autoimmune polyneuropathy. Journal of immunology (Baltimore, Md. : 1950). 2008 Dec 15;181(12):8753-60.
- [6]. Zou LP, et al. Suppression of experimental autoimmune neuritis by ABR-215062 is associated with altered Th1/Th2 balance and inhibited migration of inflammatory cells into the peripheral nerve tissue. Neuropharmacology. 2002 Apr;42(5):731-9.
- [7]. Duan RS, et al. CCR5 deficiency does not prevent P0 peptide 180-199 immunized mice from experimental autoimmune neuritis. Neurobiology of disease. 2004 Aug;16(3):630-7.
- [8]. Gonsalvez DG, et al. A Simple Approach to Induce Experimental Autoimmune Neuritis in C57BL/6 Mice for Functional and Neuropathological Assessments. Journal of visualized experiments : JoVE. 2017 Nov 09.
- [9]. Gonsalvez DG, et al. A Functional and Neuropathological Testing Paradigm Reveals New Disability-Based Parameters and Histological Features for P0180-190-Induced Experimental Autoimmune Neuritis in C57BL/6 Mice. Journal of neuropathology and experimental neurology. 2017 Feb 01;76(2):89-100.
- [10]. Zhu J, et al. Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade enhances incidence and severity of experimental autoimmune neuritis in resistant mice. Journal of neuroimmunology. 2001 Apr 02;115(1-2):111-7.
- [11]. Duan RS, et al. IL-18 deficiency inhibits both Th1 and Th2 cytokine production but not the clinical symptoms in experimental autoimmune neuritis. Journal of neuroimmunology. 2007 Feb;183(1-2):162-7.
- [12]. Zou LP, et al. Antigen-specific immunosuppression: nasal tolerance to P0 protein peptides for the prevention and treatment of experimental autoimmune neuritis in Lewis rats. Journal of neuroimmunology. 1999 Feb 01;94(1-2):109-21.
